Relmada reports Q3 net loss $22.0M; cash $106.3M; REL-1017 Phase 3 enrollment on track

RELMADA THERAPEUTICS, INC.

2023-Q3 EPS reported -$4.04

Q3 net loss $22.0M ($0.73/share) vs $39.4M ($1.31) YoY.
R&D expense $10.5M, down from $30.5M due to Reliance I/III completion.
Cash and equivalents $106.3M at Sep 30, 2023 vs $148.3M at Dec 31, 2022.
Phase 3 REL-1017 trials for MDD: Reliance II enrollment on track for H1 2024; Relight for H2 2024.
Psilocybin program: Phase 1 in steatotic liver disease to start early 2024, Phase 2a planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2023 results: net income Net loss of $22.0 million, EPS $0.73 per basic and diluted share.

Period: the three months ended September 30, 2023
Net income: Net loss of $22.0 million
EPS: $0.73 per basic and diluted share
Result: preliminary results

Exact text from the filing

Net loss for the three months ended September 30, 2023, was $22.0 million, or $0.73 per basic and diluted share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2023 results: net income Net loss of $73.6 million, EPS $2.45 per share.

Period: the nine months ended September 30, 2023
Net income: Net loss of $73.6 million
EPS: $2.45 per share
Result: preliminary results

Exact text from the filing

Net loss for the nine months ended September 30, 2023 and 2022 was $73.6 million and $119.1 million, respectively. The Company had a net loss of $2.45 and $4.04 per share for the nine months ended September 30, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-084735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.